Fact CheckerSign in

NCT06293079Completed

The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs in Patients With Multiple Sclerosis

The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs on Gait, Functional Capacity, EMG Muscle Activation and Fatigue in Patients With Multiple Sclerosis

Source: ClinicalTrials.gov · Last updated 20 Dec 2024

Brief summary (registry, in English)

The aim of our study is to compare the effects of hybrid telerehabilitation (TR)-based exercise program applied in patients with MS, only TR-based exercise program and only clinical-based exercise program on walking speed, functional capacity, peripheral muscle saturation and fatigue. Forty-five individuals with MS with EDSS scores between 0-4 will be included in the study. The patients will be randomized into three groups: Group A, Group B, and Group C. Group A- Telerehabilitation group will be included in an aerobic and strengthening exercise program over the synchronized videoconference system with the physiotherapist 2 days a week for 8 weeks. Group B- Hybrid Telerehabilitation group will be included in the same exercise program 2 days a week for 2 weeks in the clinic, and will continue remotely over the synchronized videoconference system with the physiotherapist 2 days a week for 6 weeks. In Group C-Clinical Based Rehabilitation group, the same exercise program will be applied in the clinic 2 days a week for 8 weeks. In addition to aerobic and strengthening exercises, traditional breathing exercises and energy conservation techniques will be taught to all three groups within the scope of patient education Demographic and clinical information of all patients to be included in the study will be recorded with a "Case Evaluation Form". The gait speed of the patients will be evaluated with the Timed 25-step walking test, their functional capacity with the 6-minute walking test, their Quadriceps muscle activation will be tested with the EMG muscle activation, the fatigue will be evaluated with the "Modified Fatigue Impact Scale", and the Patient Satisfaction with the "Global Rating Scale". In addition, feasibility evaluation will be made by calculating the attendance rate of the patients to the programs. All data will be evaluated by statistical analysis methods.

Status (registry)
Completed
Study type
Interventional
Enrollment
44 (actual)
First submitted
16 Feb 2024
Start date
30 Aug 2023
Primary completion date
12 Feb 2024
Lead sponsor
Biruni University
NCT number
NCT06293079

What you commit to

  • Study type: Interventional
  • Participants enrolled: 44
  • From 30 Aug 2023 to the primary completion date, 12 Feb 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Having other accompanying neurological, cardiovascular or orthopedic disorders
  • A history of MS attacks or a change in medication in the last 6 months.
  • Being in a physical condition that cannot do the exercises.
  • Comorbid conditions that negatively affect oxygen transport (severe anemia, peripheral artery diseases, etc.)

Other

  • Having hearing or vision problems.
  • Participating in any exercise program.

Who the study is looking for

  • EDSS score of 0 - 4.0
  • Having high-speed internet access via smartphone or computer
  • Getting at least 24 points from the Mini Mental Test
  • Being at Stage 3 or above according to the Functional Ambulation Scale.

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Biruni University
Coordinator of this site? Confirm its status
IstanbulTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.